UNSPSC 51384210: Piketoprofen hydrochloride

This classification denotes a nonsteroidal antiinflammatory drug C22H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0743PU79JW, chemically known as benzeneacetamide, 3-benzoyl-.alpha.-methyl-n-(4-methyl-2-pyridinyl)-, hydrochloride (1:1), but more generally known as piketoprofen hydrochloride, which bears US NIH Compound Identifier 46174105. European Medicines Agency schedules Piketoprofen hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22652.

Most nations, for tariff and trade purposes, schedule piketoprofen hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PIKETOPROFEN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCNC(C1)NC(=O)C(C)C2CCCC(C2)C(=O)C3CCCCC3.CL.

UNSPSC 51384210 Piketoprofen hydrochloride is a Commodity code with minimal alignment to recent state and local procurement activity. The code nominates a specific pharmaceutical ingredient; however, the three most recent opportunities posted under or near this classification involve naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which feature piketoprofen hydrochloride as a primary procurement objective. State and local governments are acquiring pharmaceuticals and pharmacy-related services through a mix of issuing bodies: county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). The recent procurement activity reflects demand for emergency response pharmaceuticals, pharmacy benefit program solutions, and generic medication supply chains rather than procurement of piketoprofen hydrochloride as a standalone product.

The geographic footprint of recent activity spans Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB mechanism; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, response due April 3, 2026) seeking vendor capabilities for a direct-to-manufacturer prescription program; and Minnesota's MMCAP cooperative purchasing RFP S1070000015802 (posted January 20, 2026, proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with participation from authorized wholesalers and availability effective July 1, 2026. The code shows little relevant recent activity and does not reflect actual state and local pharmaceutical procurement priorities as demonstrated by current solicitations.